10018- ACT-2 REGIONAL HEALTH DISPARITIES IN THE ERA OF COMPLEX GLIOBLASTOMA TREATMENT
Abstract Glioblastoma, a highly aggressive brain tumor, typically has a poor prognosis. However, advancements in combined treatments have significantly improved patients’ activities of daily living (ADL) and overall prognosis. Despite these advancements, patients in regional areas face challenges. Frequent hospital visits for BEV (bevacizumab) administration from remote locations often hinder the continuation of early treatment, leading to poorer outcomes. This study, conducted by the Kyushu Brain Tumour Study Group, analyzed data from patients treated at 11 hospitals in Kyushu between 2010 and 2023. The study compared survival rates based on the distance of patients’ residences from treatment centers. Prognostic factors were evaluated using both univariate and multivariate analyses. The Kaplan-Meier method was employed to compare survival rates. The findings indicated that rural glioblastoma patients may experience worse prognoses due to the long travel distances required for treatment. While consolidating treatment facilities is ideal, ensuring that such facilities are within accessible distances in rural areas is crucial for improving patient outcomes.
Authors
- Motohiro Morioka (ORCID: https://orcid.org/0000-0001-7179-1258)
- Takayuki Matsuo (ORCID: https://orcid.org/0000-0002-1430-7316)
- Junkoh Yamamoto (ORCID: https://orcid.org/0000-0002-8543-8997)
- Shinji Yamashita (ORCID: https://orcid.org/0000-0001-5859-2828)
- Koji Yoshimoto
- Daisuke Kuga (ORCID: https://orcid.org/0000-0002-9493-0748)
- Yukiko Nakahara
- Akitake Mukasa (ORCID: https://orcid.org/0000-0001-7776-9086)
- Yasutomo Momii
- Tadashi Hamasaki (ORCID: https://orcid.org/0000-0001-7968-9303)
- Kenta Ujifuku (ORCID: https://orcid.org/0000-0003-3481-8508)
- Naoki Shinojima (ORCID: https://orcid.org/0000-0003-3352-7936)
- Tetsuya Negoto (ORCID: https://orcid.org/0000-0002-3443-7513)
- Yoshiteru Nakano (ORCID: https://orcid.org/0000-0002-5436-9116)
- Hideki Nagamine
- Hirotaka Fudaba (ORCID: https://orcid.org/0000-0003-3534-2732)
- Yoshiko Okita (ORCID: https://orcid.org/0000-0002-2943-238X)
- Minoru Fujiki (ORCID: https://orcid.org/0000-0001-8642-5381)
- Nobuhiro Hata (ORCID: https://orcid.org/0000-0002-8132-0895)
- Ryosuke Hanaya (ORCID: https://orcid.org/0000-0002-4170-4878)
- Hajime Yonezawa (ORCID: https://orcid.org/0000-0003-3144-992X)
- Tatsuya Abe (ORCID: https://orcid.org/0000-0002-7215-3597)
- Hiroshi Abe (ORCID: https://orcid.org/0000-0002-8298-1329)
- Toshiyuki Emoto
Institutions
- Kurume University (JP)
- University of Miyazaki (JP)
- Kyushu University (JP)
- Saga University (JP)
- University of Occupational and Environmental Health Japan (JP)
- Oita University (JP)
- Fukuoka University (JP)
- Nagasaki University Hospital (JP)
Publication Details
- Journal
- Neuro-Oncology Advances
- Published
- 2024-11-29
- DOI
- https://doi.org/10.1093/noajnl/vdae173.027
- Primary Topic
- Biomedical Ethics and Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00